

10/564694

Patent Application

Attorney Docket No. PC25908B

IAP20 Rec'd PCT/PTO 11 JAN 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Christopher Gordon Barber, et :
al.

APPLICATION NO.: To Be Assigned

Examiner: To Be Assigned

FILING DATE: To Be Assigned

:Group Art Unit: To Be Assigned

TITLE: Compounds

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: 01/11/06

Robert T. Ronau
Robert T. Ronau

Attorney for Applicant(s)

Reg. No. 36,257

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-5910

EXPRESS MAIL NO. 9V607777895US

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC25908B				SERIALIZED To Be Assigned 107904894						
				APPLICANT Christopher Gordon Barber, et al										
				FILING DATE Herewith				GROUP To Be Assigned						
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL	US	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	US	6	3	8	0	2	1	8	04/30/02	Marfat et al	514	326		
	US	6	7	4	0	6	5	5	05/25/04	Magee et al	514	255.05		
	US	6	5	5	9	1	6	8	05/06/03	Marfat et al	514	338		
	US2002	0	1	1	1	4	5	5	08/15/02	Magee et al	546	291		
	US	6	6	4	9	6	3	3	11/18/03	Chambers et al	514	337		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	WO	9	8	4	5	2	6	4	10/15/98	International	C07D	213/82	YES	NO
	WO	0	1	5	7	0	3	6	08/09/01	International	C07D	413/12		
	WO	0	3	6	8	2	3	5	08/21/03	International	A61K	31/455		
	WO	9	1	5	7	0	2	5	08/09/01	International	C07D	405/12		
	WO	0	2	6	0	8	9	6	08/08/02	International	C07D	405/12		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
		Torphy et al., "Phosphodiesterase IV Inhibitors as Therapy for Eosinophil-induced Lung Injury in Asthma", <i>Environmental Health Perspectives</i> , 1994, 102 Suppl. 10, p. 79-84												
		Duplantier et al., "Biarylcarboxylic Acids and-amides: Inhibition of Phosphodiesterase Type IV versus [³ H]Rolipram Binding Activity and Their Relationship to Emetic Behavior in the Ferret", <i>J. Med. Chem.</i> , 1996, 39, p. 120-125												
		Schneider et al., "Discriminative Stimulus Properties of the Stereoisomers of the Phosphodiesterase Inhibitor Rolipram", <i>Pharmacology Biochemistry Behavior</i> , 1995, 50, p. 211-217												
		Banner and Page, "Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs", <i>British Journal of Pharmacology</i> , 1995, 114, p. 93-98												
		Barnette et al., "The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity", <i>J. Pharmacol. Exp. Ther.</i> , 1995, 273, p. 674-679												
		Wright et al., "Differential in vivo and in vitro bronchorelaxant activities of CP-80,633, a selective phosphodiesterase 4 inhibitor", <i>Can. J. Physiol. Pharmacol.</i> , 1997, 75, p. 1001-1008												
		Manabe et al., "Anti-inflammatory and bronchodilator properties of KF19514, a phosphodiesterase 4 and 1 inhibitor", <i>European Journal of Pharmacology</i> , 1997, 332, p. 97-107												
		Ukita et al., "Novel Potent, and Selective Phosphodiesterase-4 Inhibitors as Antiasthmatic Agents: Synthesis and Biological Activities of a Series of 1-Pyridinaphthalene Derivatives", <i>J. of Med. Chem.</i> , 1999, 42, p. 1088-1099												
EXAMINER _____ DATE CONSIDERED _____														
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

EXPRESS MAIL NO. 9607777895 US